8-K/A

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K/A

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): August 7, 2008

CHAD Therapeutics, Inc.

(Exact Name of Registrant as Specified in its Charter)

California
(State or Other Jurisdiction of Incorporation)

1-12214	95-3792700
(Commission File Number)	(I.R.S. Employer Identification No.)

10200 Mason Avenue, Suite 114
Chatsworth, California 91311

(Address of Principal Executive Offices) (Zip Code)

(818) 882-0883
(Registrant’s Telephone Number, Including Area Code)

Not Applicable
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

     On July 25, 2008, CHAD Therapeutics, Inc. (the “Company”) disclosed that it received a letter from the American Stock Exchange (“AMEX” or the “Exchange”) stating that the Company was not in compliance with Section 1003 of the AMEX Company Guide. On August 7, 2008, the Company responded to the Exchange’s letter indicating that after careful consideration, the Board of Directors of the Company determined that, at the present time, the Company is not in a position to regain compliance with the continued listing standards within the time frame required by the Exchange. Accordingly, the Company notified AMEX that it intends to voluntarily withdraw its common shares from listing on the Exchange, with such withdrawal to become effective after the close of the market on August 29, 2008.

     The Company expects to file a Form 25 with respect to the delisting with the Securities and Exchange Commission on or about August 18, 2008.

     A copy of the press release issued by the Company on August 7, 2008 regarding the delisting from the Exchange is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

The exhibit listed below is being furnished with this Form 8-K.

Exhibit
Number	Description
99.1	Press Release, dated August 7, 2008

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	CHAD Therapeutics, Inc.
Date: August 8, 2008	By:	/s/ Earl L. Yager
		Earl L. Yager
		Chief Executive Officer

EX-99.1

Exhibit 99.1

A Division of Chad Therapeutics, Inc.      Innovative Sleep Technologies	FOR IMMEDIATE RELEASE	10200 Mason Avenue #114 Chatsworth, CA 91311 Toll Free: 800.871.8484 Phone: 818.882.0883 Main Fax: 818.882.1809
Company Contact:		Investor Contact:
Earl L. Yager		Neil Berkman Associates
President and CEO		(310) 826 - 5051
www.DormioTech.com		info@BerkmanAssociates.com

CHAD Therapeutics Plans to Begin Trading
on the OTC Bulletin Board

     CHATSWORTH, California, August 7, 2008 . . . CHAD Therapeutics, Inc. (ASE:CTU) announced today that it will withdraw its common stock from the American Stock Exchange effective on August 29, 2008 because the Company no longer meets certain quantitative listing requirements, and plans to begin trading on the OTC Bulletin Board system effective on September 2, 2008, the next trading day, under the new symbol CTUI.

     On July 29, 2008, CHAD announced that its Dormio Tech division received 510(K) clearance from the FDA to market the Company’s proprietary FloCHANNEL^® Diagnostic System, Dormio’s first product for the large and rapidly growing sleep disorder market. CHAD currently expects to begin shipping this new device and associated disposables by September.

About CHAD Therapeutics

     CHAD Therapeutics, Inc. develops and markets innovative products for the sleep disorder market. For more information, visit www.dormiotech.com.

Safe Harbor Statements under the Private Securities Litigation Reform Act of 1995.

     The foregoing statements regarding prospects for future earnings and revenues, future sales trends and the introduction of products under development are forward-looking statements that involve certain risks and uncertainties. A number of important factors could cause actual results to differ materially from those contemplated by such forward-looking statements. These include the introduction of new products with perceived competitive advantages over the Company’s products, changes or proposed changes in health care reimbursement which affect home care providers, and DORMIO’s ability to anticipate and respond to technological and economic changes in the sleep market. Moreover, the success of the Company’s products and products under development will depend on their efficacy, reliability and the health care community’s perception of the products’ capabilities and benefits, the degree of acceptance the products achieve among sleep labs and patients, and, with respect to products under development, obtaining timely regulatory approval. Additional factors that could cause actual results to differ materially from those contemplated in this press release can be found in the Company’s annual and quarterly reports filed with the Securities and Exchange Commission under the caption “Outlook: Issues and Risks.”

* * * * *

#456x

Flochannel Is a Registered Trademark of Chad Therapeutics, Inc.
Iso 13485 Certified Company
WWW.DORMIOTECH.COM

la-990672